Search
for
Sort by
Research 61–90 of 775
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Discovery of a novel and highly selective JAK3 inhibitor as a potent hair growth promoter
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- 1332 Janus kinase inhibitor increases hair growth by increasing beta-catenin activity in outer root sheath cells
- The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Balance of tofacitinib efficacy and disease flare in the treatment of alopecia universalis: A case report and review of the literature
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- Role of janus kinase inhibitors in the treatment of alopecia areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
- Alopecia areata: from immunopathogenesis to emerging therapeutic approaches
- The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
- A novel therapeutic paradigm for patients with extensive alopecia areata
- Dysregulation of Leukaemia Inhibitory Factor (LIF) Signalling Pathway by Supraphysiological Dose of Testosterone in Female Sprague Dawley Rats During Development of Endometrial Receptivity
- Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry about?
- Alopecia Areata
- Ruxolitinib for the treatment of severe alopecia areata
- Pharmacological Treatment of Alopecia
- Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- Current and future pharmacotherapy for alopecia areata
- JAK1 gain-of-function variant causes alopecia areata, atopic dermatitis, and autoimmune thyroid disease
- Clinical Perspectives on Alopecia: From Hair Follicle Biology to Advanced Therapies
- Real-World Experience of Tofacitinib and Baricitinib Use in Alopecia Areata in Greek Population: A Retrospective Analysis With Focus on Safety
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management